Clinical Trial Results:
A Phase III randomized, double blind, placebo controlled, multicenter study
of panobinostat for maintenance of response in patients with Hodgkin’s
lymphoma who are at risk for relapse after high dose chemotherapy and
autologous stem cell transplant
Summary
|
|
EudraCT number |
2009-014846-26 |
Trial protocol |
FR BE GB NL DE ES IT |
Global completion date |
14 May 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
06 Oct 2016
|
First version publication date |
06 Oct 2016
|
Other versions |
|
Summary report(s) |
CLBH589E2301.CTR.06Sept2016 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.